ASE 2026

Aurora, CO

Gaylord Rockies Resort

June 26 - June 28, 2026

For HCM and cardiac amyloidosis, the average patient waits 2 to 5 years for a diagnosis. At hospitals using Viz Cardio Suite, that window drops to three months. Join us at ASE 2026 to see how Viz Cardio Suite helps cardiology teams identify high-risk patients earlier, standardize monitoring across care settings, and accelerate referrals and follow-up.

Viz Cardio™ Suite

The Viz Cardio Suite spans acute and chronic cardiovascular conditions across the full cardiology service line.

Viz.ai uses artificial intelligence to detect suspected disease and notify care teams with high-fidelity mobile image viewing, patient information, and secure communication tools that help coordinate care and support treatment decisions. Trusted by more than 2,000 hospitals across the US and EMEA, Viz.ai has been shown to improve care team coordination and accelerate clinical workflows.

Viz.ai was ranked the #1 AI-Powered Clinical Decision Support platform in the 2026 Black Book survey of 1,237 healthcare leaders, earning the top score in 13 of 18 evaluation criteria. That includes #1 rankings for clinical detection accuracy, speed-to-treatment, workflow orchestration, clinical evidence and outcome support, and overall enterprise value.

Learn more about Viz Cardio Suite.